Rapid Transition From Inhaled Iloprost to Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension

Cardiovascular Therapeutics - United Kingdom
doi 10.1111/1755-5922.12008
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Inhaled Iloprost for Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2002English

Prs9 - Switching From Subcutaneous Treprostinil to Inhaled Treprostinil in Pulmonary Arterial Hypertension Treatment and Economic Impact Evaluation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Tolerability and Clinical Efficacy of Inhaled Treprostinil in Patients With Group 1 Pulmonary Arterial Hypertension

Therapeutic Advances in Chronic Disease
Medicine
2018English

Treatment Satisfaction Is Associated With Improved Quality of Life in Patients Treated With Inhaled Treprostinil for Pulmonary Arterial Hypertension

Health and Quality of Life Outcomes
MedicineEnvironmentalPublic HealthOccupational Health
2013English

Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension From Intravenous Epoprostenol to Intravenous Treprostinil

American Journal of Cardiology
Cardiovascular MedicineCardiology
2007English

Hemodynamic and Gas Exchange Effects of Inhaled Iloprost in Patients With COPD and Pulmonary Hypertension

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2017English

Experience With Inhaled Iloprost and Bosentan in Portopulmonary Hypertension

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2007English

Inhaled Iloprost Is a Potent Acute Pulmonary Vasodilator in HIV‐related Severe Pulmonary Hypertension

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2004English

Effects of Inhaled Aviptadil (Vasoactive Intestinal Peptide) in Patients With Pulmonary Arterial Hypertension (PAH)

2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy